Shanghai Pharmaceuticals Holding Co (2607) Stock Statistics & Valuation Metrics

Shanghai Pharmaceuticals Holding Co has a market cap or net worth of HK$64.70B. The enterprise value is HK$82.01B.

Shanghai Pharmaceuticals Holding Co has 919,072,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shanghai Pharmaceuticals Holding Co’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 4.97%.

The current PE Ratio of Shanghai Pharmaceuticals Holding Co is 12.9. Shanghai Pharmaceuticals Holding Co’s PEG ratio is 0.26.

In the last 12 months, Shanghai Pharmaceuticals Holding Co had revenue of 283.58B and earned 5.72B in profits. Earnings per share was 1.54.

In the last 12 months, operating cash flow was 9.91B and capital expenditures -2.26B, giving a free cash flow of 7.64B billion.

Shanghai Pharmaceuticals Holding Co pays an annual dividend of HK$0.117, resulting in a dividend yield of 5.93%

Shanghai Pharmaceuticals Holding Co upcoming earnings date is Oct 30, 2026, TBA (Confirmed).

Shanghai Pharmaceuticals Holding Co as a current ratio of 1.33, with Debt / Equity ratio of 84.16%

In the past 12 months, Shanghai Pharmaceuticals Holding Co has paid 2.85B in taxes.

Shanghai Pharmaceuticals Holding Co EV to EBITDA ratio is 3.80, with an EV/FCF ratio of 14.28.

Shanghai Pharmaceuticals Holding Co has HK$45.98B in cash and marketable securities with HK$65.92B in debt, giving a net cash position of -HK$19.94B billion.

Gross margin is 10.79%, with operating margin of 3.51%, and net profit margin of 2.02%.

The average price target for Shanghai Pharmaceuticals Holding Co is HK$16.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy